- Home
- KALA vs TPST Comparison
KALA vs TPST Comparison
Compare KALA & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- TPST
- Stock Information
- Founded
- KALA 2009
- TPST 2011
- Country
- KALA United States
- TPST United States
- Employees
- KALA 43
- TPST N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- TPST Health Care
- Exchange
- KALA Nasdaq
- TPST Nasdaq
- Market Cap
- KALA 27.3M
- TPST 27.2M
- IPO Year
- KALA 2017
- TPST N/A
- Fundamental
- Price
- KALA $5.92
- TPST $0.71
- Analyst Decision
- KALA Strong Buy
- TPST Strong Buy
- Analyst Count
- KALA 2
- TPST 4
- Target Price
- KALA $15.00
- TPST $20.00
- AVG Volume (30 Days)
- KALA 31.3K
- TPST 1.5M
- Earning Date
- KALA 11-12-2024
- TPST 11-12-2024
- Dividend Yield
- KALA N/A
- TPST N/A
- EPS Growth
- KALA N/A
- TPST N/A
- EPS
- KALA N/A
- TPST N/A
- Revenue
- KALA N/A
- TPST N/A
- Revenue This Year
- KALA N/A
- TPST N/A
- Revenue Next Year
- KALA N/A
- TPST N/A
- P/E Ratio
- KALA N/A
- TPST N/A
- Revenue Growth
- KALA N/A
- TPST N/A
- 52 Week Low
- KALA $4.21
- TPST $0.70
- 52 Week High
- KALA $9.25
- TPST $6.00
- Technical
- Relative Strength Index (RSI)
- KALA 41.69
- TPST 27.47
- Support Level
- KALA $5.67
- TPST $0.86
- Resistance Level
- KALA $6.23
- TPST $0.83
- Average True Range (ATR)
- KALA 0.31
- TPST 0.07
- MACD
- KALA -0.07
- TPST -0.01
- Stochastic Oscillator
- KALA 21.55
- TPST 4.33
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.